An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration
Source · ClinicalTrials.gov: elamipretide
TLDR
ClinicalTrials.gov lists as completed an open-label, Phase 1 study evaluating elamipretide’s safety and tolerability in intermediate age-related macular degeneration. The single-center study planned approximately 40 participants over 12 weeks; the excerpt provides no results.
- 01The study focused on safety and tolerability.
- 02Participants included a high-risk drusen subgroup without geographic atrophy and a noncentral geographic atrophy subgroup.
- 03Completion status alone does not establish safety or efficacy.
Why it matters Editorial
The listing documents clinical evaluation of elamipretide in intermediate age-related macular degeneration, but provides no outcome data.
Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.
ClinicalTrials.gov: elamipretide
ClinicalTrials.gov: elamipretide
ClinicalTrials.gov: elamipretide
ClinicalTrials.gov: elamipretide